Revelation Biosciences REVB 深 滬
等待開盤 04-01 09:30:00 美东时间
1.20
+0.010
+0.84%
華盛通- 最 高1.27
- 今 開1.22
- 成交量 11.57万股
- 最 低 1.18
- 昨 收 1.19
- 總市值 446.45万
- 52周最高 44.16
- 市盈率 靜 --
- 換手率 3.11%
- 52周最低 1.06
- 委 比 90.39%
- 總股本 372.04万
- 歷史最高 2276064.00
- 量 比 1.20
- 振 幅 7.56%
- 歷史最低 1.18
- 每 手 1
- 風險率 11.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026
- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30,
03-30 21:02
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients
Revelation Biosciences says Gemini normalizes inflammation in PRIME study CKD patients Revelation Biosciences presented additional PRIME Study analyses at AKI & CRRT 2026 on March 29, 2026, highlighting Gemini effects in stage 3-4 chronic kidney disease patients. Data showed Gemini normalized cellul
03-30 21:02
Revelation Biosciences Shareholders Approve Warrant Share Issuance
Revelation Biosciences ( ($REVB) ) has shared an announcement. On March 18, 202...
03-20 04:51
Revelation Biosciences reports FY results
Revelation Biosciences press release (REVB): FY net loss of $59.76. As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024...
02-27 20:02
Revelation Biosciences Q4 EPS $(1.65) Misses $(0.96) Estimate
Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(0.96) by 71.88 percent. This is a 97.24 percent increase over losses of $(59.76) per
02-27 05:49
Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_01292026_REVB_Sorensen.pdf
01-29 23:14
Revelation Biosciences Announces 1-for-4 Reverse Stock Split
Revelation Biosciences Announces 1-for-4 Reverse Stock Split Revelation Biosciences Inc. announced a 1-for-4 reverse stock split of its common stock, effective January 28, 2026. The stock will begin trading on a post-split basis under the existing symbol "REVB" on that date. The reverse split aims t
01-26 22:55
Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise
Revelation Biosciences Raises $11 Million Through Immediate Warrant Exercise Revelation Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, allowing holders to purchase up to 13,065,000 shares of common stock at a reduced exercise price of $0.86 per share. In conne
01-26 15:33
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its acute kidney injury treatment.
01-23 15:02
